Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06677112 | RECRUITING | Endometrial Cancer

MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
Sponsor:

Rachel Miller

Information provided by (Responsible Party):

Rachel Miller

Brief Summary:

This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. This study will gather information to help determine the best way to evaluate lymph nodes during surgery for endometrial cancer.

Condition or disease

Endometrial Cancer

Intervention/treatment

Selective surgical staging

REFLEX

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 625 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Randomized Phase 3 Study of SELECTIVE SURGICAL STAGING Versus REFLEX Lymphadenectomy in Non-mappers Undergoing Sentinel Lymph Node Sampling for the Treatment of Endometrial Cancer
Actual Study Start Date : 2025-03-17
Estimated Primary Completion Date : 2030-01
Estimated Study Completion Date : 2030-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy
  • * Histologically or cytologically confirmed carcinoma of the endometrium confined to the uterine corpus
  • * No clinical evidence of extra-uterine disease on pre-operative evaluation. Preoperative evaluation to rule-out extra-uterine disease may include a CT scan, MRI or ultrasound. Note: preoperative imaging is not mandatory for study enrollment.
  • * Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy.
  • Neoadjuvant chemotherapy for this endometrial cancer is not allowed.
  • * Life expectancy (estimated survival) of at least 6 months.
  • * AST(SGOT)/ALT(SGPT) \< 3.0X upper limit of normal
  • * Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
  • * GOG Performance Status greater than 2 (Appendix II)
  • * Uterine sarcoma
  • * Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam
  • * Previous vaginal, pelvic or abdominal irradiation
  • * Chemotherapy, hormone therapy or immunotherapy directed at the present disease
  • * Previous pelvic lymphadenectomy or retroperitoneal surgery
  • * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen should be excluded
  • * Known allergy to iodine or indocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition
  • * Patients with uncontrolled intercurrent illness
  • * Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • * Pregnant or lactating women. Women of child-bearing potential will be excluded if they have a positive serum/urine pregnancy test
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer

Location Details

NCT06677112

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Kentucky

University of Kentucky

Lexington, Kentucky, United States, 40506